{
  "company": {
    "name": "Obsidian Therapeutics",
    "website": "https://obsidiantx.com/",
    "record": "https://startuphistory.org/c/obsidiantx.com"
  },
  "status": null,
  "history_since": "2016-08-24T03:24:15.000Z",
  "baseline": {
    "snapshot_id": "c576dcf65b187ccf7889f30b619df5a98a5b79cd3ab70d4dfd5dbb29450e4a6d",
    "observed_at": "2018-08-28T16:53:20.000Z",
    "headline": null,
    "description": "Obsidian is developing next-generation cell and gene therapies with pharmacologic operating systems",
    "evidence": "https://web.archive.org/web/20180828165320/https://obsidiantx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:51:04.010Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2021-01-21T17:19:49.000Z",
      "variants": [
        {
          "headline": "At Obsidian, we are pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases",
          "subhead": null,
          "observed_at": "2020-04-08T17:37:33.000Z",
          "evidence": "https://web.archive.org/web/20200408173733/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "At Obsidian, we are pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases",
          "subhead": null,
          "observed_at": "2021-01-21T17:19:49.000Z",
          "evidence": "https://web.archive.org/web/20210121171949/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "At Obsidian, we are pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases",
      "subhead": null,
      "from": "2020-04-08T17:37:33.000Z",
      "to": "2021-01-21T17:19:49.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20210121171949/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2020-04-08T17:37:33.000Z",
          "to": "2021-01-21T17:19:49.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2022-01-14T04:59:22.000Z",
      "variants": [
        {
          "headline": "Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients with solid tumors",
          "subhead": null,
          "observed_at": "2022-01-14T04:59:22.000Z",
          "evidence": "https://web.archive.org/web/20220114045922/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients with solid tumors",
      "subhead": null,
      "from": "2022-01-14T04:59:22.000Z",
      "to": "2022-01-14T04:59:22.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20220114045922/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2022-01-14T04:59:22.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T17:51:04.010Z",
      "variants": [
        {
          "headline": "Unlocking the Promise of Precision Cell and Gene Therapy",
          "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
          "observed_at": "2023-01-13T11:18:48.000Z",
          "evidence": "https://web.archive.org/web/20230113111848/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Unlocking the Promise of Precision Cell and Gene Therapy",
          "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
          "observed_at": "2024-07-20T17:07:03.000Z",
          "evidence": "https://web.archive.org/web/20240720170703/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Unlocking the Promise of Precision Cell and Gene Therapy",
          "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
          "observed_at": "2025-07-22T07:51:59.000Z",
          "evidence": "https://web.archive.org/web/20250722075159/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Unlocking the Promise of Precision Cell and Gene Therapy",
          "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
          "observed_at": "2026-07-12T14:25:07.000Z",
          "evidence": "https://web.archive.org/web/20260712142507/https://obsidiantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Unlocking the Promise of Precision Cell Therapy",
          "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
          "observed_at": "2026-11-06T17:51:04.010Z",
          "evidence": "https://obsidiantx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Unlocking the Promise of Precision Cell Therapy",
      "subhead": "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.",
      "from": "2023-01-13T11:18:48.000Z",
      "to": "2026-11-06T17:51:04.010Z",
      "captures": 5,
      "evidence": "https://obsidiantx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2023-01-13T11:18:48.000Z",
          "to": "2026-11-06T17:51:04.010Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-c576dcf65b187ccf7889f30b619df5a98a5b79cd3ab70d4dfd5dbb29450e4a6d:f3104665e5ad241320e1553c4adc3f66fdc594b93b2c0b70ac60304f44fc82a7:compliance:784f18463d850bcc",
      "before_evidence": "https://web.archive.org/web/20180828165320/https://obsidiantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "compliance",
      "label": "Compliance",
      "summary": "Now states FDA-APPROVED compliance on its homepage.",
      "between": {
        "from": "2018-08-28T16:53:20.000Z",
        "to": "2020-04-08T17:37:33.000Z"
      },
      "evidence": "https://web.archive.org/web/20200408173733/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-compliance"
    },
    {
      "n": 2,
      "id": "page-83fa92f3001de5977bf5b94a13537b724c4b4ce466ed182af0c80f6a6d9c60e2:0a7a13117143e55ee199cee911f5e6586e5cf708c80f5d581fde20f0ea44bb5c:headline:60ce0d1d48482df9",
      "before_evidence": "https://web.archive.org/web/20210121171949/https://obsidiantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “At Obsidian, we are pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable dise…” to “Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients with solid tumors”.",
      "between": {
        "from": "2021-01-21T17:19:49.000Z",
        "to": "2022-01-14T04:59:22.000Z"
      },
      "evidence": "https://web.archive.org/web/20220114045922/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 3,
      "id": "page-0a7a13117143e55ee199cee911f5e6586e5cf708c80f5d581fde20f0ea44bb5c:8c5004cdc32a8c667cf370012c61f7322da70863e8279ffb31eea400b18eac26:headline:2f923443f2309672",
      "before_evidence": "https://web.archive.org/web/20220114045922/https://obsidiantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients with solid tumors” to “Unlocking the Promise of Precision Cell and Gene Therapy”.",
      "between": {
        "from": "2022-01-14T04:59:22.000Z",
        "to": "2023-01-13T11:18:48.000Z"
      },
      "evidence": "https://web.archive.org/web/20230113111848/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 4,
      "id": "page-0a7a13117143e55ee199cee911f5e6586e5cf708c80f5d581fde20f0ea44bb5c:8c5004cdc32a8c667cf370012c61f7322da70863e8279ffb31eea400b18eac26:compliance:784f18463d850bcc",
      "before_evidence": "https://web.archive.org/web/20220114045922/https://obsidiantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "compliance",
      "label": "Compliance",
      "summary": "Now states FDA-APPROVED compliance on its homepage.",
      "between": {
        "from": "2022-01-14T04:59:22.000Z",
        "to": "2023-01-13T11:18:48.000Z"
      },
      "evidence": "https://web.archive.org/web/20230113111848/https://obsidiantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-compliance"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Obsidian Therapeutics” company record, https://startuphistory.org/c/obsidiantx.com"
}